Biomarker Clinical Phase Outsourcing Services Market Analysis

Biomarker Clinical Phase Outsourcing Services Market Analysis

To get key market trends

  Download Free Sample

Based on biomarker type, the market is segmented into surrogate endpoints, predictive biomarker, prognostic biomarker, safety biomarker, and other biomarker types. The surrogate endpoints segment held the largest business share at 54.6% in 2023. The growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis are driving the growth of the surrogate endpoints segment.
 

• The use of surrogate endpoints in clinical trials has several advantages, including reducing the time and cost of clinical trials, facilitating the approval of new drugs, and guiding treatment decisions and assessing the effectiveness.
   
• Moreover, a surrogate endpoint is clearly shown to predict a beneficial effect through appropriate studies, its use generally allows clinical studies to be conducted in smaller numbers of people over shorter periods of time, thus leading to its acceptance and affordability.
   

Based on therapeutic area, the biomarker clinical phase outsourcing services market is classified into oncology, neurology, cardiology, autoimmune disease, other therapeutic areas. The oncology segment is expected to reach the largest market revenue of USD 12.7 billion by 2032.
 

• Oncology has been at the forefront in the utilization of biomarkers for various clinical phases of different diagnostics and therapeutic areas. For instance, according to the report of The Journal of Precision Medicine in 2022, more than 55% of all cancer trials from 2018 to 2020 involved the use of biomarkers, compared with 15% in 2000. Therefore, outsourcing services specialized in oncology biomarkers leverage these technologies for comprehensive molecular profiling and analysis.
   

Based on end-user, the biomarker clinical phase outsourcing services market is segmented into pharmaceutical companies, biotechnology companies, and other end-users. The biotechnology companies’ segment is expected to exhibit 19.4% CAGR between 2024 – 2032 period.
 

• Biotechnology companies have increasingly adopted outsourcing strategies to streamline their operations and focus on core competencies. Outsourcing biomarker clinical phase services allows these companies to leverage external expertise and resources.
   
• Additionally, outsourcing services offer flexibility and scalability to biotechnology companies. As biomarker research needs fluctuate during different phases of clinical trials, outsourcing allows for the adjustment of resources and services accordingly. These firms leverage outsourcing for efficient, flexible, and globally compliant biomarker services, cementing their central role in the market.
   

In 2023, North America held a significant share of 42.1% in the biomarker clinical phase outsourcing services market.
 

• The region boasts advanced healthcare infrastructure, including state-of-the-art research facilities and laboratories. This infrastructure supports clinical trials, attracting firms seeking outsourcing services along with easy access to cutting-edge technologies and resources.
   
• Moreover, North America hosts few of the world's leading contract research organizations, fostering a robust environment for biomarker clinical phase outsourcing services. Such aforementioned factors are expected to propel the demand for biomarker clinical phase outsourcing services in the North America market.